Sat, Dec 20, 2014, 10:31 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Aeterna Zentaris Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • pfw2141 pfw2141 Nov 19, 2012 2:50 PM Flag


    I try to paste it, I hope the message boards take it.........................

    7:32AM Aeterna Zentaris: Data demonstrate that perifosine combined with temsirolimus was well tolerated in Phase 1 trial in malignant glioma (AEZS) 1.93 : Co announced that perifosine, its oral
    AKT inhibitor, combined with temsirolimus, was well tolerated in an investigator driven Phase 1 clinical trial in recurrent or progressive malignant glioma. Preliminary survival results demonstrated that median overall survival was 7.4 months. There were 27 radiographic responses: complete response (0), partial response (2), stable disease (13) and progressive disease (12). Combination therapy with TEM = 115 mg weekly and perifosine 100 mg daily (following 600 mg load) was well tolerated in heavily pre-treated adults with recurrent MGs. Accrual ongoing at dose level 5 and MTD has not yet been defined.

    Sentiment: Strong Buy

0.610.00(+0.41%)Dec 19 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.